SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin launched via the Runes protocol, generating buzz for its fair distribution and strong community. Discussions highlight its potential to drive utility and transaction volume on the Bitcoin network, with many touting it as a leader in the current cycle. Community members are actively promoting its unique position compared to other meme coins and speculating about potential exchange listings.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid speculation around a potential licensing deal with AstraZeneca, with community members discussing the impact of recent trial data and a possible buyout. Some investors are analyzing trial endpoints and revenue potential, while others are comparing SMMT to competitors like IOVA. The community is closely watching for further developments and official announcements.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the Bitcoin memecoin gains traction within the crypto community, with many touting its fair launch and strong community backing. Conversation highlights its potential to become the meme face of Bitcoin and draw comparisons to other popular memecoins. Community members are emphasizing its organic growth and decentralized nature.

DOVU

DOVU.X is trending as the community highlights its staking rewards and potential in the Real World Asset (RWA) space, particularly due to its "Trust Operating System." Recent news around partnerships and deals related to carbon credits and ecological projects may be acting as a catalyst. Community members are actively discussing its association with Hedera and potential for significant growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a significant land sale agreement, potentially boosting its NAV. The community is discussing the stock's low float and potential for a substantial price increase, with some highlighting potential squeeze dynamics. Bullish sentiment appears to be building, driven by the company's real estate assets and upcoming shareholder meeting.

K9 Finance, a Shibarium-based LSD platform, offers core DeFi services and acts as an official validator. Rewarding $KNINE holders with $BONE for block validation, it aims to drive DeFi adoption via the 'Roundtable of Dogs' DAO, which governs treasury and roadmap decisions.

K9 Finance DAO

K9 Finance DAO ($KNINE.X) is trending due to the upcoming K9 Quest Airdrop and its role as a key player in Shibarium's DeFi ecosystem, offering liquid staking for $BONE.X. The community is actively discussing staking strategies, DAO governance, and ways to earn rewards through Bonecrusher and ShibaSwap integration. With its innovative tri-token system and focus on real yield, K9 Finance is positioned to drive DeFi adoption on Shibarium.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending following a strong earnings report, with community members discussing the impressive EPS figures. Bullish sentiment is fueled by solid inside and fuel margins, although revenue slightly missed expectations. The company's strategic focus on prepared foods and expansion plans are also key talking points.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to confirmed new government orders for medical countermeasures, driving optimism about revenue and profitability. The community is actively discussing the potential for a short squeeze given the high short interest and upcoming investor conferences. Some investors speculate about a potential takeover, pointing to the company's cash position and strategic assets.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors digest the latest earnings report and guidance, with community members actively discussing the company's market position and future growth prospects. While some express disappointment, others point to positive aspects of the report and reiterate long-term bullish sentiment, viewing any price drops as buying opportunities. Technical analysis and analyst ratings are also contributing to the ongoing conversation around $CHWY.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending amid discussions about its gene therapy pipeline and recent safety data from a Phase 3 trial; the community is weighing the long-term potential against short-term risks. Some traders are focusing on analyst ratings and potential for a sector rotation, while others discuss potential acquisition scenarios and ARK Invest's position in the stock. Overall, the conversation revolves around the balance between gene editing's promise and the volatility of clinical trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit US equity futures are slightly higher , hovering near all time highs as traders bet that data on Friday will bolster the case for interest rate...

Mizuho lifts targets on storage and memory stocks on strong AI demand

Investing.com -- Mizuho raised its price targets on key storage and memory stocks, Seagate,  Western Digital  (NASDAQ:WDC), and SanDisk, in a note Thursday, citing accelerating demand driven by AI infrastructure. 

Goldman Sachs bullish on LRCX, AMAT, and STX  in new semiconductor call

Investing.com -- Goldman Sachs initiated coverage on U.S. semiconductor capital equipment, storage, and foundry stocks in a note Thursday, holding a “balanced view,” highlighting mid-cycle dynamics that present selective opportunities. 

Flash storage solutions provider Sandisk Corp. (SNDK), which&nbsp;spun off publicly from Western Digital (WDC) in February, received a bullish&nbsp;call from a Wall Street firm.<a href="https://stocktwits.com/symbol/SNDK">Sandisk stock</a> has gained about 29% since its spin-off in February.Jefferies analyst Blayne Curtis initiated coverage of Sandisk stock with a ‘Buy’ rating and a $60 price target,&nbsp;The Fly reported. The stock price target implies roughly a 30% upside from Thursday’s close.Curtis believes the spin-off could unlock shareholder value as updated technology drives enterprise solid state drives market share gains.&nbsp;The analyst sees&nbsp;an upside to estimates If SanDisk's content trends sustain amid tariffs.Last week, Benchmark added Sandisk stock to its “Best Ideas” list and raised the price target to $62 from $58. The firm maintained a ‘Buy’ rating on the stock. The research firm based its optimism on its view that the NAND business was entering a cyclical upturn, driven by artificial intelligence (AI) opportunities and double-digit&nbsp;growth in data center spending.The&nbsp;research firm believes that SanDisk's next-generation products, namely BiCS8 chips and ultra QLC technology, will drive share gains in the enterprise solid-state drive (SSD) market.In early June, the company announced a secondary offering of its shares held by its erstwhile parent, Western Digital, with the offering&nbsp;comprising 18.54 million shares priced at $38.50&nbsp;each.&nbsp;On Stocktwits, retail sentiment toward Sandisk stock was ‘bearish’ by early Monday, worsening from the ‘neutral’ mood a day ago. The message volume was ‘low.’<figure class="image"><img style="aspect-ratio:622/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_4_36_41_AM_png_5282c1af92.webp" alt="Screenshot 2025-07-07 at 4.36.41 AM.png" width="622" height="53"><figcaption>SNDK sentiment and message volume as of 4:37 a.m. ET, July 7 | source: Stocktwits</figcaption></figure>Sandisk ended Thursday’s session up 0.43% at $46.41.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-reportedly-offers-us-government-steep-discounts/chFtfACR5TN">Oracle Reportedly Offers US Government Steep Discounts: Retail Traders Raise Eyebrows As Stock Scales New Peaks</a>

In this photo illustration, the SanDisk Corporation logo is displayed on a smartphone screen. 

Sandisk Gets Bullish Initiation From Jefferies, But Retail Sentiment Lags

Analyst Blayne Curtis believes the spin-off could unlock shareholder value as updated technology drives the enterprise solid-state drive maker’s market share gains. 

Equity

Analyst Blayne Curtis believes the spin-off could unlock shareholder value as updated technology drives the enterprise solid-state drive maker’s market share gains. 


Citi starts Sandisk at Buy on NAND recovery and enterprise SSD push; stock rises

Investing.com -- Citi Research has begun coverage of SanDisk Corporation (NASDAQ:SNDK) with a Buy rating and a $57 price target, which implies roughly 21% upside from the stock’s Wednesday closing price.

BofA starts Sandisk at Buy on margin upside, NAND recovery prospects

Investing.com -- Sandisk Corp was initiated with a Buy rating and a price objective of $61 by BofA, which sees the flash storage maker as a key beneficiary of an early-stage recovery in NAND pricing and improving operating margins.

This 1 Unlikely Small-Cap Is an S&P Standout in 2025, But Is It a Buy Right Now?

With Western Digital’s spinoff complete, SanDisk makes its mark in the S&P SmallCap 600. So, is this a wise time to pay attention?

Flash and advanced memory technology company Sandisk Corp. (SNDK) began trading as an independent public&nbsp;entity on Feb. 24, following its separation from Western Digital Corp. (WDC).This marked a relisting of the stock as Sandisk was a public-traded company before it was acquired by Western Digital in 2016.Since its relisting, Sandisk's stock has risen about 40%, even amid the broader market volatility.&nbsp;On Tuesday, Morgan Stanley analyst Joseph Moore initiated coverage of SanDisk stock with an ‘Overweight’ rating and a $84 price target, suggesting a 67% upside potential.The analyst noted that in 2024, Sandisk had a 14% share of the global market for NAND, a non-volatile storage technology that does not require power to retain data. Considering its partnership with its development/manufacturing joint venture partner Kioxia, Sandisk's global market share increases to 30%.Moore noted that the NAND cycle recovered from the 2024 lows, and the improvement increased utilization, resulting in a modestly oversupplied situation.Morgan Stanley expects the NAND market to be tough in the first half of 2025. Nevertheless, it is expected to have a 90% upside in twelve months as cyclical drivers reverse for an underappreciated franchise, it added.Moore said, “Despite uncertainty, this is one of the best risk/rewards in our coverage.”Stocktwits users are largely bullish on&nbsp;<a href="https://stocktwits.com/symbol/SNDK">Sandisk stock</a>.&nbsp;One user said the stock is grossly undervalued and has huge upside potential.<stembedurl>https://stocktwits.com/milieupower/message/606049893</stembedurl>Another user was bullish about the company’s technology. According to them, a new high bandwidth flash (HBF) patent could have applications for every computer.<stembedurl>https://stocktwits.com/milieupower/message/606049893</stembedurl>At last check, Sandisk stock was down 2.98% at $48.65 amid the broader market weakness.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/super-micro-stock-bucks-trump-tariff-induced-broader-market-weakness/chejs6URCF">Super Micro Stock Bucks Trump Tariff-Induced Broader Market Weakness: Retail Persists With Bullish Stance</a>

SanDisk adapter and microSD card are seen in this illustration photo taken in Krakow, Poland on January 30, 2023.

Sandisk Analyst Predicts Nearly 70% Upside For Relisted Stock: Retail’s Excited

Since its Feb. 24 listing, Sandisk stock has risen about 40%, even amid the broader market volatility. 

Sandisk Celebrates Nasdaq Listing After Completing Separation from Western Digital

Sandisk Corporation, a global Flash and advanced memory technology innovator, today announced that the company has completed its separation from Western Digital and is now an independent public...

Shares of Leslie's Inc. (LESL) dropped over 5% in after-hours trading Wednesday after news of its removal from the S&amp;P SmallCap 600 index dampened retail sentiment.SanDisk (SNDK) will replace Leslie's in the index before trading opens on Tuesday, Feb. 25. According to The Fly, Western Digital Corp. (WDC), an S&amp;P 500 member, is spinning off SanDisk in a deal set to close on Feb. 24.Western Digital will remain in the S&amp;P 500 post-spin-off, while Leslie's market capitalization was deemed no longer "representative of the small-cap market space."On Wednesday, Stifel analyst W. Andrew Carter reportedly cut Leslie's price target to $1.30 from $1.55, maintaining a 'Sell' rating. Carter noted that the company needs a significant second-half rebound but has "limited room for error."On Tuesday, BofA double downgraded Leslie's to 'Underperform' from 'Buy,' slashing its price target to $1.40 from $2.65. The firm cited market share losses, weak FY25 guidance, and subdued free cash flow.Leslie's reported mixed Q1 results this month, with a loss per share (EPS) of $0.22, slightly missing estimates of $0.21. Revenue rose 0.7% to $175.23 million, beating forecasts of $173.4 million. Adjusted net loss widened to $41.3 million from $36.8 million a year ago.On Stocktwits, sentiment turned 'bearish' from 'neutral' just a day ago, with message volume remaining low.<figure class="image"><img style="aspect-ratio:1320/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_02_20_at_1_11_45_PM_4b10519f1d.png" alt="Screenshot 2025-02-20 at 1.11.45 PM.png" width="1320" height="312"><figcaption>LESL sentiment meter and message volume on Feb 20 as of 3:00 am ET</figcaption></figure>Leslie’s is a direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals.Leslie’s stock is down 0.45% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

Leslie's Stock Slips After Losing Spot In S&P SmallCap 600, Retail Sentiment Turns Bearish

Leslie’s recently reported mixed first-quarter results.

SanDisk Corp. engages in the development, manufacture, and provision of storage devices and solutions on NAND flash technology. Its products include solid state drives. embedded products, removable cards, universal series bus, and wafers and components. The company was founded on February 5, 2024 and is headquartered in Milipitas, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.85	--	--	N/A
Q4 '25	--	$0.29	--	N/A

SNDK
Sandisk Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest SNDK News

SNDK Sandisk Corp